Imigran

Sumatriptan, the active ingredient in Imigran, is a selective serotonin 5‑HT1B/1D receptor agonist presented as a tablet for oral use. It is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients. It provides rapid relief of migraine pain and associated symptoms such as nausea, photophobia and phonophobia.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is distributed under a prescription‑only status.

Sumatriptan is used to treat migraine, a neurovascular headache disorder, by targeting serotonergic pathways.

Migraine with aura: provides rapid relief of headache pain and associated symptoms. Migraine without aura: aborts the attack and reduces nausea, photophobia, and phonophobia. Acute migraine attacks (any type): offers an oral option for quick symptom control.

Sumatriptan may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in fingers or face - Nausea or abdominal pain

Serious or Rare Side Effects: - Coronary artery spasm or myocardial infarction - Serotonin syndrome, especially with other serotonergic agents - Allergic reactions such as rash, angioedema, or anaphylaxis

When prescribing Imigran, clinicians should consider several safety factors.

Cardiovascular assessment: avoid use in patients with ischemic heart disease, uncontrolled hypertension, or history of coronary artery spasm. Concomitant serotonergic drugs: review use of SSRIs, SNRIs, MAO inhibitors to reduce risk of serotonin syndrome. Pregnancy and lactation: prescribe only if benefit outweighs potential risk; safety data are limited. Age restrictions: safety and efficacy not established in children; use is limited to adult patients. Drug interactions: assess for ergot alkaloids and other vasoconstrictors before prescribing. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Sumatriptan can interact with several medication classes, requiring careful review.

Major Interactions (Avoid): - Ergot alkaloids: combined vasoconstriction can cause severe coronary spasm. - MAO inhibitors: increased serotonergic activity may precipitate serotonin syndrome. - Other triptans: additive vasoconstrictive effects raise cardiovascular risk.

Moderate Interactions (Monitor Closely): - SSRIs, SNRIs, or other serotonergic antidepressants: monitor for signs of serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise sumatriptan plasma concentrations. - Antihypertensive agents: sumatriptan can enhance blood pressure‑lowering effects.